2026 Addiction Treatment and Substance Use Disorder (SUD) Market Update: A Rebounding Market Focused on Quality

Acquisition activity within the substance use disorder treatment sector has been characterized by a significant flight to quality in recent years. While underperforming assets face limited exit options, high-quality, compliant operators continue to attract interest from PE-backed platforms seeking regional density and differentiated clinical capabilities. Independent owners with strong compliance programs, favorable payer relationships, measurable clinical outcomes, and scalable infrastructure may be particularly well positioned in the current consolidation cycle which is much more selective than the previous phase of consolidation.

This opportunity particularly extends to businesses that span the full continuum of integrated care, offering step down programs for intermediate level acuity patients. Programs such as Partial Hospital Programs (PHP) and Intensive Outpatient Programs (IOP) continue to occupy an important position in the continuum by bridging the gap between traditional outpatient treatment and higher-acuity residential settings. Within the outpatient segment, the market spans primary mental health, substance abuse, and complex dual-diagnosis programs, with each sub-segment representing a distinct and addressable growth opportunity for investors.

The U.S. substance use disorder (SUD) sector sits at a critical intersection of public health necessity and institutional investment. The global substance abuse treatment market size is projected to grow from $15 billion in 2026 to nearly $33 billion by 2034, representing a compound annual growth rate (CAGR) of 10%.¹ According to the 2025 U.S. National Survey on Drug Use and Health, nearly 45 million Americans aged 12 years or older met diagnostic criteria for a substance use disorder in 2025, and fewer than 20% of people who needed substance use treatment actually reported receiving treatment in the past year.²

For investors, the combination of persistent demand, a fragmented provider landscape, regulatory barriers to entry, and the operational complexity of delivering high-quality care has increased the strategic value of compliant and well-run organizations. Providers that have developed integrated outpatient, residential, medication-based, or dual-diagnosis capabilities may therefore attract a premium relative to less differentiated operators that are focused on specific modalities.

• Private Equity-Backed SUD Platforms: Established treatment platforms frequently pursue add-on acquisitions to expand into new markets, increase regional density, add clinical capabilities, and strengthen referral networks. Select examples include Bradford Health Services (backed by Lee Equity Partners) and Sero Mental Health (backed by Lindsay Goldberg).
• Thesis-Driven Private Equity Firms & Family Offices: Healthcare private equity groups focused on specific modalities to drive operational improvements, such as RC Capital (invested in The Blanchard Institute) and MKH Capital Partners (invested in Haven Health Management).
• Large, Diversified Strategic Operators: Publicly-traded, nationwide operators with significant scale and a broad range of services, such as Acadia Healthcare and Universal Health Services.

Below is a list of strategic consolidators that have been active in recent years. This list is based on PGP’s firsthand experience advising clients through transactions in the Substance Use Disorder space.

• Premium Valuation Allocation for Quality Platforms. While transaction volume has cooled, institutional sponsors and strategic buyers continue to place a premium for business with strong regulatory and compliance infrastructure.
• Increasing Operational and Billing Complexity. Remaining independent has become more demanding as commercial payors increase administrative hurdles, tighten prior authorization requirements, and execute forensic-level audits on insurance receivables. Managing utilization reviews requires capital expenditures that negatively impact the bottom line. For smaller organizations, these requirements can place meaningful pressure on margins and management resources.
• Succession Planning and Liquidity Optionality. Partnering with a PE-backed platform or executing a full recapitalization allows founder-owners to de-risk personal balance sheets and monetize equity. These corporate structures provide immediate back-office relief, allowing owners to focus on clinical excellence while funding expansions.
• Stable Platform Environment. PE-backed strategic platforms have focused efforts inward in recent years to improve operational efficiencies and integrate recently acquired programs. Platforms are now picking their heads up to reinvigorate M&A as part of their growth strategy.

PGP has been covering the space for years and has been diligently tracking transaction activity and valuations. Based on our proprietary conversations and data, the market is starting to show signs of rebounding as larger consolidators start to refocus on inorganic growth and family offices and private equity firms look to reenter the space.

The substance use disorder sector is entering a more mature phase of consolidation, moving away from indiscriminate acquisition activity of the low interest rate era, and shifting toward a disciplined flight to quality. Several large private equity-backed platforms have spent the past several quarters entirely focused on debt restructuring, billing optimization, and platform integration. As selected platforms stabilize and approach later stages of their investment hold periods, private equity sponsors may increasingly seek high-quality independent providers that can support growth, increase regional density, and strengthen the strategic positioning of the platform ahead of a future recapitalization or exit.

This environment may create a highly favorable competitive dynamic for premium independent operators with clean billing histories, robust clinical outcomes, and strong management teams. Providers that prepare early, address potential diligence issues, and conduct a competitive process may be able to achieve stronger transaction terms, attractive rollover-equity economics, and partnership structures aligned with their clinical and financial objectives.